Close

Impact

SegAna has developed a platform technology that can be used to enhance cancer treatments of organs and soft tissue, where the dose delivered can be quickly modified to suit the current tumor location and motion.

Icon
Value Proposition

SegAna’s technology enables tumor and normal tissue position shifts, which allows radiation oncologists to plan and deliver advanced treatments. Some of these advanced approaches include:

  • Reducing the primary target volume (PTV) to only encompass the tumor and effectively spare normal tissues
  • Increasing the treatment dose to the tumor now that the precise tumor location is known
  • Performing Adaptive Radiotherapy (ART), where the dose delivered can be quickly modified to suit the current tumor location and motion
  • Performing quality assurance tests in a patient-specific manner to determine an accurate dose and reduce the number of treatment sessions (or fractions)

 These approaches may reduce the cost of therapy, increase treatment effectiveness, and improve the quality of life.

Icon
Milestones

The Founders have been researching this concept over several years, which was funded through research grants that lead to several publications. The investments to date have enabled SegAna to optimize its cloud-based software for adaptive radiotherapy. Some of the technology’s publications describe the linear elastic algorithm that is used in SegAna’s software which provides accurate tissue detail between radiation treatment fractions. SegAna was also recently awarded an SBIR Phase I Grant in January 2018 for its software technology, “Cloud-based Automated Dose Accumulation for Online Adaptive Radiotherapy”. SegAna is aggressively moving forward with its software technology and expects to submit for an SBIR Phase II grant in October 2018 to continue the technology’s advancement as well as submit a 510(k) in Q4 2018 to introduce its first product in Q1 2019.

Icon
Platform Technology

SegAna has developed a platform technology that can be used to enhance cancer treatments of organs and soft tissue, where the dose delivered can be quickly modified to suit the current tumor location and motion.